{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Protective Agent[C26170]" in comments (approximate match)
Status:
US Approved Rx
(2006)
Source:
NDA021902
(2006)
Source URL:
First approved in 1992
Source:
21 CFR 358A
Source URL:
Class:
MIXTURE
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First marketed in 1921
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03538327: Phase 4 Interventional Completed Hypertension
(2013)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Tidiacic (thiazolidine-2,4-dicarboxylic acid) is a hepatoprotective drug that acts as an antioxidant and a sulfur donor. Tidiacic is a component of tidiacic arginine that used in France for the treatment of toxic liver damage
Status:
US Approved Rx
(2010)
Source:
BLA125293
(2010)
Source URL:
First approved in 2010
Source:
BLA125293
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2002)
Source:
BLA103946
(2002)
Source URL:
First approved in 2000
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00833989: Phase 2 Interventional Completed Ischaemic Attack, Transient
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04176133: Phase 2 Interventional Completed Healthy
(2019)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
PROTEIN
